LATEST CANCER TREATMENTS
IN THE WORLD
From bispecific antibodies and antibody-drug conjugates to mRNA cancer vaccines โ a comprehensive look at the newest therapies transforming cancer care globally.
Cancer Treatment Is Evolving Faster Than Ever
The oncology landscape is advancing rapidly. Multiple new drug classes, combination regimens, and platform technologies have entered clinical practice, offering patients options that did not exist even two years ago.
โMore cancer therapies were approved in the last three years than in the entire previous decade combined.โ
Breakthrough Drug Classes Reshaping Oncology
Several new categories of cancer drugs have moved from clinical trials to standard practice.
Bispecific Antibodies
Engineered proteins that simultaneously bind a tumor antigen and a T-cell receptor, creating a direct immune bridge. Examples: teclistamab, mosunetuzumab.
Antibody-Drug Conjugates (ADCs)
Monoclonal antibodies linked to cytotoxic payloads for targeted drug delivery. Examples: trastuzumab deruxtecan (Enhertu), sacituzumab govitecan.
mRNA Cancer Vaccines
Personalized vaccines encoding tumor neoantigens to prime immune response. Moderna/Merck's mRNA-4157 showing promise in melanoma adjuvant setting.
Next-Gen CAR-T
Allogeneic (off-the-shelf) CAR-T, dual-targeting constructs, and armored CAR-T with built-in safety switches and cytokine co-stimulation.
Key Recent Global Approvals
Notable cancer drug approvals from 2024-2025.
| Drug / Therapy | Type | Indication | Status |
|---|---|---|---|
| Trastuzumab Deruxtecan (Enhertu) | ADC | HER2-low breast cancer | FDA/EMA approved |
| Teclistamab (Tecvayli) | Bispecific Ab | r/r multiple myeloma | FDA/EMA approved |
| Lifileucel (Amtagvi) | TIL therapy | Advanced melanoma | FDA approved 2024 |
| Tarlatamab (Imdelltra) | Bispecific Ab | Small cell lung cancer | FDA approved 2024 |
| mRNA-4157 + Keytruda | mRNA vaccine combo | Adjuvant melanoma | Phase 3 trials |
| Carvykti (cilta-cel) | BCMA CAR-T | Earlier-line myeloma | Expanded indication |
Key Milestones in Cancer Treatment
- 75+New oncology drugs approved globally 2023-2025
- 6FDA-approved CAR-T products
- 2,000+Active cancer clinical trials worldwide
- 50%+Melanoma 5-year survival with immunotherapy
Tumor-Agnostic Treatments: Beyond Cancer Type
A paradigm shift: drugs approved based on genetic markers rather than where the cancer originated.
MSI-High / dMMR Tumors
Pembrolizumab (Keytruda) approved for any solid tumor with microsatellite instability-high or mismatch repair deficiency.
NTRK Fusion-Positive
Larotrectinib and entrectinib approved for cancers harboring NTRK gene fusions regardless of tissue origin.
RET Fusion-Positive
Selpercatinib approved across tumor types for RET gene alterations.
Frequently Asked Questions
About Latest Cancer Treatments
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Want to Know If a New Treatment Fits Your Case?
Upload your medical reports and our team will evaluate eligibility for the latest treatment options worldwide.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.